Cephadone 1 Gram Injection (Cefazolin Sodium)

Adult administration

For infections caused by Gram-positive bacteria, administer 1 to 2 g (potency) once daily, divided into 2 to 3 intravenous injections. For infections caused by Gram-negative bacteria, 3 to 4 g (potency) may be divided into 2 to 3 doses daily. In cases of life-threatening infections and infections caused by moderately susceptible bacteria, the dose may be increased up to 6 g (potency) daily. For solution preparation, dissolve 1 g (potency) in 5 mL of injection water and inject slowly over 2 to 3 minutes.

This drug should not be used in patients with hypersensitivity to cephalosporin antibiotics, premature infants, or neonates. Careful administration is required for pregnant women in the first trimester, patients with kidney or liver dysfunction, patients with hemophilia or thrombocytopenia, and patients with gastrointestinal ulcers. Additionally, patients who cannot take oral medications, are receiving parenteral nutrition, elderly patients, and those in poor general condition should be closely monitored for vitamin K deficiency symptoms. Mild hypersensitivity reactions such as headaches, dizziness, or nausea may occur while using this drug, and rarely, serious allergic reactions such as skin rashes, fever, or anaphylaxis may occur, requiring immediate discontinuation and appropriate treatment. Liver function test results may temporarily increase, and leukopenia may rarely occur, necessitating regular blood tests. Severe colitis, abdominal pain, and frequent diarrhea may occur in the gastrointestinal tract, requiring immediate discontinuation if these symptoms appear. If respiratory problems such as fever, cough, or difficulty breathing occur, the administration should be stopped, and appropriate treatment should be received. Rarely, dysbiosis, such as stomatitis or candidiasis may occur. Symptoms of bleeding tendency due to vitamin K deficiency or vitamin B deficiency may also appear, and these should be closely monitored. This medication should only be used for a suitable period as determined by sensitivity tests to prevent the development of resistant bacteria, and thorough history-taking and skin reaction tests should be conducted prior to administration. During administration, emergency treatment preparations should be made to handle shock reactions and the patient should be monitored in a stable condition. Considering the increased resistance of first-generation cephalosporins, reference to sensitivity test results is essential. Caution should be exercised when using this drug in conjunction with other antibiotics such as aminoglycosides, as it may worsen renal dysfunction. There is also a risk of renal impairment when used with polymyxin B, colistin, or high-dose diuretics. When administered with high-dose oral anticoagulants, close monitoring of blood coagulation status is required. Breastfeeding individuals should use this medication cautiously, as it may pass into breast milk in small amounts. Lastly, this drug should not be mixed with aminoglycoside antibiotics in the syringe for injection.

Serious side effects

Anaphylaxis (severe allergic reaction), interstitial pneumonia, respiratory distress due to PIE syndrome, severe colitis, symptoms of vitamin K deficiency, bleeding tendency related to hemophilia and thrombocytopenia

Mild side effects

• Transient mild headache
• dizziness
• nausea
• skin rash
• fever
• vomiting
• loss of appetite
• blood in stools
• abdominal pain
• frequent diarrhea

This drug should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to keep it away from direct sunlight and store it at room temperature, specifically at a normal indoor temperature that is neither too hot nor too cold.

Appearance

A colorless transparent vial filled with white to pale yellow powder

Package unit

1 gram/vial [1g x 10 vials]